RxDoctor Payments DataLook up a doctor →

Fay Bembry, NP

Psychiatric/Mental Health · Johnson City, TNNPI 1811098908

Payments from drug & device makers

$449,078in general payments, 2019–2025

Across 1,153 payments — averaging $389.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$171K
  • Neurocrine Biosciences, Inc.$91K
  • Acadia Pharmaceuticals Inc$87K
  • Avanir Pharmaceuticals, Inc.$53K
  • Teva Pharmaceuticals USA, Inc.$46K
  • Corium, LLC$571
  • plus $498 from 6 others

What the payments were for

  • Consulting fees$31,8867%
  • Speaking & faculty fees$308,70769%
  • Travel & lodging$88,25520%
  • Food & beverage$19,9524%
  • Education$2760%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$449,078 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$178,860
Medicare patients
373
Services billed
2,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine64$386,756
NuplazidPimavanserin Tartrate40$121,696
AristadaAripiprazole Lauroxil12$39,100
NuedextaDextromethorphan Hbr/Quinidine53$34,256
RexultiBrexpiprazole46$28,599
Divalproex Sodium1,032$20,215
Trazodone Hcl2,042$10,608
Buspirone Hcl1,114$8,639
Memantine Hcl561$7,687
Quetiapine Fumarate897$6,562
Mirtazapine872$6,512
TrintellixVortioxetine Hydrobromide52$6,419
Aripiprazole134$4,746
Duloxetine Hcl170$4,352
DayvigoLemborexant12$4,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$45,617$386,75664 claims
Acadia Pharmaceuticals IncNuplazid$87,222$121,69640 claims
Avanir Pharmaceuticals, Inc.Nuedexta$53,206$34,25653 claims
Otsuka America Pharmaceutical, Inc.Rexulti$171,166$28,59946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →